about us:


Olon S.p.A. is a worldwide leader in the development and production of APIs (Active Pharmaceutical Ingredients). The ideal partner for custom synthesis and contract manufacturing projects.

news & events:


products search:


focus on:


OLAPARIB

Olon S.p.A. is going to finalise  its development of API OLAPARIB. The product is a poly-ADP-Ribose polymerase inhibitor and it is used for the treatment of ovarian cancer.

NINTEDANIB

Olon S.p.A. is going to finalise  its development of API NINTEDANIB.

The product is an angiogenesis inhibitor and it is used for the treatment of idiopathic pulmonary fibrosis (IPF).

NINTEDANIB will join other cytotoxics for cancer therapy already in our portfolio, such as clofarabine, irinotecan, tofacitinib citrate.